Role of antileukotrienes in acute asthma exacerbations | Zendy

Domenico Lorenzo Urso | Zendy; Daniele Vincenzo | Zendy; Lorenzo Formaro | Zendy; Ada Federico | Zendy; G. Urso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of antileukotrienes in acute asthma exacerbations

Author(s) -

Domenico Lorenzo Urso,

Daniele Vincenzo,

Lorenzo Formaro,

Ada Federico,

G. Urso

Publication year - 2012

Publication title -

reviews in health care

Language(s) - English

Resource type - Journals

eISSN - 2038-6702

pISSN - 2038-6699

DOI - 10.7175/rhc.1553275-81

Subject(s) - medicine , asthma , asthma exacerbations , b2 receptor , intensive care medicine , inhalation , asthma management , anesthesia , bradykinin , receptor

Acute asthma exacerbations are one of the most frequent reasons to visit the emergency department or general practitioner. Although current standard treatments for acute asthma – including supplemental oxygen, short-acting β2-agonists, systemic corticosteroids and anticholinergics – are quite effective in most patients, they are inadequate for rapid and sustained improvement in a significant proportion. The antileukotrienes, a relatively new class of drugs, have a role in the treatment of chronic asthma. Their relatively rapid onset of action after endovenous or oral administration and their additive effect to β2-agonists led to the hypothesis that they might be of benefit in acute asthma. This review examines the efficacy of antileukotrienes in the treatment of acute asthma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research